Phase II Study of Olaparib in Men With High-Risk Biochemically-Recurrent Prostate Cancer Following Radical Prostatectomy, With Integrated Biomarker Analysis
Phase of Trial: Phase II
Latest Information Update: 18 Feb 2019
At a glance
- Drugs Olaparib (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 16 Feb 2018 Trial design presented at the 2018 Genitourinary Cancers Symposium.
- 02 May 2017 Status changed from not yet recruiting to recruiting.